OKT3 and IL-2 Treatment for Purging of the Latent HIV-1 Reservoir in Vivo Results in Selective Long-Lasting CD4+ T Cell Depletion (original) (raw)
REFERENCES
Ellenhorn JD, Woodle ES, Ghobreal I, Thistlethwaite JR, Bluestone JA: Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation 50:608-612, 1990 Google Scholar
Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337-342, 1985 Google Scholar
Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517, 1999 Google Scholar
Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber B, Markowitz M, Ho DD: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340:1605-1613, 1999 Google Scholar
Wong JK, Hezareh M, Günthard HF, Havlir D, Ignacio CC, Spina CA, Richman DD: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295, 1997 Google Scholar
Finzi D, Hermankova M, Pierson T, Carruth L, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant JE, Markowitz M, Ho DD, Richman DD, Siliciano RF: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300, 1997 Google Scholar
Ho DD: Toward HIV eradication or remission: The tasks ahead. Science 280:1866-1869, 1998 Google Scholar
Chun T-W, Engel D, Mizell SB, Ehler LA, Fauci AS: Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 188:83-91, 1998 Google Scholar
Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586, 1996 Google Scholar
Meuer SC, Hussey RE, Cantrell DA, Hodgdon JC, Schlossman SF, Smith KA, Reinherz EL: Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway. Proc Natl Acad Sci USA 81:1509-1513, 1984 Google Scholar
Prins JM, Jurriaans S, van Praag RME, Blaak H, van Rij R, Schellekens PThA, ten Berge IJM, Yong S-L, Fox CH, Roos MTL, de Wolf F, Goudsmit J, Schuitemaker H, Lange JMA: Immunoactivation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13:2405-2410, 1999 Google Scholar
Fraser C, Ferguson NM, Ghani AC, Prins J, Lange J, Goudsmit J, Anderson RM, de Wolf F: Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose dependent and restricted by the potency of antiretroviral drugs. AIDS 14:659-669, 2000 Google Scholar
Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, Julian BA, Barber WH, Laskow DA, Diethelm AG, Curtis JJ: OKT3 first-dose reaction: Association with T cell subsets and cytokine release. Kidney Int 39:141-148, 1991 Google Scholar
Parlevliet KJ, Bemelman FJ, Yong SL, Hack CE, Surachno J, Wilmink JM, ten Berge IJ, Schellekens PT: Toxicity of OKT3 increases with dosage: A controlled study in renal transplant recipients. Transpl. Int. 8:141-146, 1995 Google Scholar
Buysmann S, Hack CE, van Diepen FN, Surachno J, ten Berge IJ: Administration of OKT3 as a two-hour infusion attenuates firstdose side effects. Transplantation 64:1620-1623, 1997 Google Scholar
Ferran C, Dy M, Merite S, Sheehan K, Schreiber R, Leboulenger F, Landais P, Bluestone J, Bach JF, Chatenoud L: Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation 50:642-648, 1990 Google Scholar
Hamann D, Baars PA, Rep MHG, Hooibrink B, Kerkhof-Garde SR, Klein MR, van Lier RAW: Phenotypic and functional separation of memory and effector Human CD8pos T cells. J Exp Med 186:1407-1418, 1997 Google Scholar
Giorgi JV, Ho HN, Hirji K, Chou CC, Hultin LE, O'Rourke S, Park L, Margolick JB, Ferbas J, Phair JP: CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: Development of HLA-DR+ CD38-CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. J Infect Dis 170:775-781, 1994 Google Scholar
Bemelman FJ, Buysmann S, Yong SL, van Diepen FN, Schellekens PT, ten Berge RJM: Biphasic granulocytopenia after administration of the first dose of OKT3. J Lab Clin Med 126:571-579, 1995 Google Scholar
Buysmann S, Bemelman FJ, Schellekens PT, van Kooyk Y, Figdor CG, ten Berge IJM: Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3. Blood 87:404-411, 1996 Google Scholar
Goldstein G, Fuccello AJ, Norman DJ, Shield CF, Colvin RB, Cosimi AB: OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 42:507-511, 1986 Google Scholar
Muller TF, Grebe SO, Neumann MC, Heymanns J, Radsak K, Sprenger H, Lange H: Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 64: 1432-1437, 1997 Google Scholar
Wong JT, Eylath AA, Ghobrial I, Colvin RB: The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging. Transplantation 50:683-689, 1990 Google Scholar
Janssen O, Wesselborg S, Kabelitz D: Immunosuppression by OKT3-Induction of programmed cell death (apoptosis) as a possible mechanism of action. Transplantation 53:233-234, 1992 Google Scholar
Mackall CL, Fleisher TA, Brown M, Andrich MP, Chen C, Feuerstein IM, Horowitz ME, Magrath IT, Shad AT, Steinberg SM, Wexler LH, Gress RE: Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 332:143-149, 1995 Google Scholar
Mackall CL: Distinctions between CD8+ and CD4+ T cell regenerative pathways result in prolonged T cell subset imbalance after intensive chemotherapy. Blood 89:3700-3707, 1997 Google Scholar
Heitger A, Neu N, Kern H, Panzer-Grümayer E-R, Greinix H, Nachbaur D, Niederwieser D, Fink FM: Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation. Blood 90:850-857, 1997 Google Scholar
Rep MH, Van Oosten BW, Roos MT, Ader HJ, Polman CH, van Lier RA: Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. J. Clin. Invest. 99:2225-2231, 1997 Google Scholar
de Gast GC, Verdonck LF, Middeldorp JM, The TH, Hekker A, Linden JA, Kreeft HA, Bast BJ: Recovery of T cell subsets after autologous bone marrow transplantation is mainly due to proliferation of mature T cells in the graft. Blood 66:428-431, 1985 Google Scholar
Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM: Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 103:1391-1398, 1999 Google Scholar
Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, Bach JF: In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49: 697-702, 1990 Google Scholar
Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De Pauw L, Wybran J, Kinnaert P, Dupont E, Toussaint C: Release of tumor necrosis factor, interleukin-2, and gammainterferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47:606-608, 1989 Google Scholar
Davey RT, Jr., Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Fyfe G, Lane HC: Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 175:781-789, 1997 Google Scholar
Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Jr., Falloon J, Polis MA, Walker RE, Stevens R, Salzman NP, Metcalf JA, Masur H, Lane HC: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 332:567-575, 1995 Google Scholar
Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Jr., Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 335:1350-1356, 1996 Google Scholar
Luster AD. Chemokines-Chemotactic cytokines that mediate inflammation. N Engl J Med 338:436-445, 1998 Google Scholar